135333-25-4

Basic information

• Product Name: 2-bromo-2-methoxypropiophenone
• Synonyms: 2-bromo-2-methoxypropiophenone;2-bromo-1-(2-methoxyphenyl)propan-1-one
• CAS NO: 135333-25-4
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.09714
• Mol File: 135333-25-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 40 °C
• Boiling Point: 289.0±15.0 °C(Predicted)
• Appearance: /
• Density: 1.388±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-bromo-2-methoxypropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-2-methoxypropiophenone(135333-25-4)
• EPA Substance Registry System: 2-bromo-2-methoxypropiophenone(135333-25-4)

Safety Data

• Hazardous Substances Data: 135333-25-4(Hazardous Substances Data)

Upstream product

• 5561-92-2 1-(2-methoxyphenyl)propan-1-one 
• 135-02-4 ortho-anisaldehyde 
• 7452-01-9 1-(o-methoxyphenyl)-1-propanol 

Downstream Products

• 113234-63-2 1-(2-methoxyphenyl)-2-(triphenylphosphaneylidene)propan-1-one 
• 5561-92-2 1-(2-methoxyphenyl)propan-1-one 
• 74132-07-3 2-(2-methoxyphenyl)-3-methylquinoxaline 
• 312307-16-7 3-(2-methoxybenzoyl)-2-cyanobutyronitrile 

Relevant articles and documents

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor

The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.

Fe-Catalyzed Cycloisomerization of Aryl Allenyl Ketones: Access to 3-Arylidene-indan-1-ones

A cycloisomerization of aryl allenyl ketones to 3-arylidene-indan-1-ones using a cationic Fe-complex as a catalyst is reported. The catalyst opens a synthetically interesting reaction pathway to this surprisingly underrepresented class of indanones that are not accessible using alternative catalytic systems.

PYRIDAZINONE COMPOUNDS AS CALCILYTICS

Various calcilytic compounds and pharmaceutical compositions containing these compounds are disclosed. Calcilytic compounds are compounds capable of inhibiting calcium receptor activity. Methods for preparing calcilytic compounds, oral bioavailability of calcilytic compounds, and their use as calcium receptor antagonists are also disclosed.